Leadership of the Fox Chase Cancer Center is under the direction of its President and Chief Executive Officer, Michael V. Seiden, M.D., Ph.D.;the Deputy Director (DD) and Chief Scientific Officer (CSO),Jonathan Chernoff, M.D., Ph.D.;the Associate Director for Academics (AD-A) and Chief Academic Officer (CAO), J. Robert Beck M.D.;the Associate Director for Networks (AD-N) and Chief Network Officer (CNO), Paul Engstrom, M.D.;and the Associate Director for Clinical Research (AD-CR), Massimo Cristofanilli, M.D, (see Cancer Center Organizational chart on the cover of this section). Seiden has complete authority over all activities of the Center including faculty appointments. Center space and institutional monies. He reports to the Board of Directors. The DD is responsible for the Center's Research Programs, Shared Resources and Research Administration. The AD-A manages the faculty appointment and promotion process, training programs, mentoring. Institutional Review Board, and extramural relationships. The AD-N is responsible for disseminating best practices and working with the Center's extensive network of affiliates. The AD-CR has responsibility for the Protocol Office and clinical research management, including the Research Review Committee. This CCSG-funded Cancer Center leadership group is a subset of Fox Chase Cancer Center's Senior Leadership Council (SLC), which meets weekly to direct all activities of the Center. Included in the SLC are the Chief Operating Officer, Chief Financial Officer, Chief Development Officer, and the Senior Vice President for Business Development and Clinical Operations. The five Cancer Center leaders establish overall research priorities, foster the continued integration of scientific and medical programs, discuss and set recruiting priorities, create senior level search committees, review and approve faculty promotions, and discuss current issues facing Fox Chase Cancer Center and its scientific faculty and staff. In addition, Seiden meets with the DD and AD-A at least weekly (usually daily). The team also makes decisions concerning optimal use of CCSG resources. Examples include reorganizing the Research Programs and Shared Resources, recruiting senior leaders {e.g., Cristofanilli), and empowering Program and Resource leaders. Senior Leadership has recruited 21 faculty since Seiden's assuming the Presidency in 2007.

Public Health Relevance

The Senior Leadership of the Cancer Center is responsible for the organization and administration of the Center and the CCSG. As such the composition, function and effectiveness of the Senior Leadership has immense relevance to the CCSG as a whole.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006927-48
Application #
8335529
Study Section
Subcommittee G - Education (NCI)
Project Start
2011-07-21
Project End
2014-06-30
Budget Start
2011-07-21
Budget End
2012-06-30
Support Year
48
Fiscal Year
2011
Total Cost
$2,163,644
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 25:1384
Nikonova, Anna S; Deneka, Alexander Y; Kiseleva, Anna A et al. (2018) Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD). FASEB J 32:2735-2746
Singh, Tanu; Lee, Eric H; Hartman, Tiffiney R et al. (2018) Opposing Action of Hedgehog and Insulin Signaling Balances Proliferation and Autophagy to Determine Follicle Stem Cell Lifespan. Dev Cell 46:720-734.e6
Di Marcantonio, Daniela; Martinez, Esteban; Sidoli, Simone et al. (2018) Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia. Clin Cancer Res 24:608-618
Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 24:3513-3527.e7
Gabbasov, Rashid; Xiao, Fang; Howe, Caitlin G et al. (2018) NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice. Oncogene 37:4854-4870
Jones, Caitlin E; Hammer, Anisha M; Cho, YouJin et al. (2018) Stromal PTEN Regulates Extracellular Matrix Organization in the Mammary Gland. Neoplasia 21:132-145
Fahl, Shawn P; Coffey, Francis; Kain, Lisa et al. (2018) Role of a selecting ligand in shaping the murine ??-TCR repertoire. Proc Natl Acad Sci U S A 115:1889-1894
Campbell, Kerry S; Cohen, Adam D; Pazina, Tatiana (2018) Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma. Front Immunol 9:2551
Shaikh, Talha; Wang, Lora S; Egleston, Brian et al. (2018) Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer. Am J Clin Oncol 41:59-64

Showing the most recent 10 out of 1280 publications